Glucotrack Receives USPTO Approval for Three Patents on CBGM Platform

Glucotrack, a medical device company focused on diabetes technologies, has received USPTO approval for three patents for its continuous blood glucose monitoring (CBGM) platform. The patents protect key technologies in Glucotrack's CBGM system, a long-term implantable device designed for multi-year sensor longevity. This strengthens the company's competitive position and intellectual property protection as it advances its fully implantable CBGM system toward commercialization.